Home Cart Sign in  
Chemical Structure| 4401-71-2 Chemical Structure| 4401-71-2

Structure of 4401-71-2

Chemical Structure| 4401-71-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 4401-71-2 ]

CAS No. :4401-71-2
Formula : C7H10N2O2
M.W : 154.17
SMILES Code : O=C1N(C)C(C(C)=CN1C)=O
MDL No. :MFCD00154763
InChI Key :BHWQEVXICGSHEW-UHFFFAOYSA-N
Pubchem ID :78112

Safety of [ 4401-71-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 4401-71-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.43
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 42.45
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

44.0 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.79
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.23
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.61
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.07
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.4
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.26

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.05
Solubility 13.6 mg/ml ; 0.0882 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.24
Solubility 89.4 mg/ml ; 0.58 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.96
Solubility 16.8 mg/ml ; 0.109 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.4 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.82

Application In Synthesis of [ 4401-71-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 4401-71-2 ]

[ 4401-71-2 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 110-91-8 ]
  • dl-trans-5-bromo-6-hydroxy-1,3-dimethyl-5,6-dihydrothymine [ No CAS ]
  • [ 4401-71-2 ]
  • (5S,6S)-5-Hydroxy-1,3,5-trimethyl-6-morpholin-4-yl-dihydro-pyrimidine-2,4-dione [ No CAS ]
  • (5S,6R)-5-Hydroxy-1,3,5-trimethyl-6-morpholin-4-yl-dihydro-pyrimidine-2,4-dione [ No CAS ]
  • 2
  • [ 96-48-0 ]
  • [ 4401-71-2 ]
  • 5-<(2-oxotetrahydro-3-furyl)methyl>-1,3-dimethyluracil [ No CAS ]
  • [ 55377-23-6 ]
  • 4
  • [ 4401-71-2 ]
  • [ 110-82-7 ]
  • [ 144459-85-8 ]
  • [ 55377-23-6 ]
  • 5
  • [ 4401-71-2 ]
  • [ 127-09-3 ]
  • Acetic acid (4R,5S)-5-hydroxy-1,3,5-trimethyl-2,6-dioxo-hexahydro-pyrimidin-4-yl ester [ No CAS ]
  • 6
  • [ 4401-71-2 ]
  • [ 64-19-7 ]
  • [ 100201-54-5 ]
  • 7
  • [ 4401-71-2 ]
  • [ 64-19-7 ]
  • [ 32079-08-6 ]
  • 8
  • [ 4401-71-2 ]
  • [ 113-00-8 ]
  • [ 15981-91-6 ]
  • 9
  • [ 4401-71-2 ]
  • [ 937-14-4 ]
  • 3-Chloro-benzoic acid (4S,5R)-5-hydroxy-1,3,5-trimethyl-2,6-dioxo-hexahydro-pyrimidin-4-yl ester [ No CAS ]
  • 10
  • [ 4401-71-2 ]
  • [ 134461-75-9 ]
  • [ 10320-84-0 ]
  • [ 107097-10-9 ]
  • [ 4869-46-9 ]
  • [ 14181-46-5 ]
  • 11
  • [ 4401-71-2 ]
  • [ 540-51-2 ]
  • [ 144329-45-3 ]
  • 12
  • [ 4401-71-2 ]
  • [ 94-36-0 ]
  • [ 144459-85-8 ]
  • [ 55377-23-6 ]
  • 13
  • [ 4401-71-2 ]
  • [ 94-36-0 ]
  • 5-<(2-oxotetrahydro-3-furyl)methyl>-1,3-dimethyluracil [ No CAS ]
  • [ 55377-23-6 ]
  • 14
  • [ 4401-71-2 ]
  • (cis, anti)-1,3-dimethyluracyl dimer [ No CAS ]
  • [ 7025-74-3 ]
  • 15
  • [ 4401-71-2 ]
  • [ 5176-82-9 ]
  • [ 23450-35-3 ]
  • cis-1,3,5-dimethyl-5,6-dihydroxy-5,6-dihydrouracil [ No CAS ]
  • [ 4869-46-9 ]
  • 16
  • [ 4401-71-2 ]
  • [ 100186-95-6 ]
  • tras-1,3,5-trimethyl-5,6-dihydroxy-5,6-dihydro uracil [ No CAS ]
  • 17
  • [ 4401-71-2 ]
  • 5-chloro-6-hydroxy-1,3-dimethyl-5,6-dihydrothymine [ No CAS ]
  • 19
  • [ 7033-39-8 ]
  • [ 75-24-1 ]
  • [ 874-14-6 ]
  • [ 4401-71-2 ]
  • 20
  • [ 119-61-9 ]
  • [ 4401-71-2 ]
  • 3,5-diaza-1,3,5-trimethyl-8-oxa-7,7-diphenylbicyclo[4.2.0]octane-2,4-dione [ No CAS ]
  • 3,5-diaza-1,3,5-trimethyl-7-oxa-8,8-diphenylbicyclo[4.2.0]octane-2,4-dione [ No CAS ]
  • 21
  • [ 611-97-2 ]
  • [ 4401-71-2 ]
  • (Z)-2,4,6-trimethyl-8,8-bis(4-methylphenyl)-7-oxa-2,4-diazabicyclo[4.2.0]octane-3,5-dione [ No CAS ]
  • (Z)-2,4,6-trimethyl-7,7-bis(4-methylphenyl)-8-oxa-2,4-diazabicyclo[4.2.0]octane-3,5-dione [ No CAS ]
  • 22
  • [ 4401-71-2 ]
  • [ 32446-66-5 ]
  • (Z)-7,7-bis(4-cyanophenyl)-2,4,6-trimethyl-8-oxa-2,4-diazabicyclo[4.2.0]octane-3,5-dione [ No CAS ]
  • (Z)-8,8-bis(4-cyanophenyl)-2,4,6-trimethyl-7-oxa-2,4-diazabicyclo[4.2.0]octane-3,5-dione [ No CAS ]
  • 23
  • [ 4401-71-2 ]
  • [ 90-98-2 ]
  • (Z)-8,8-bis(4-chlorophenyl)-2,4,6-trimethyl-7-oxa-2,4-diazabicyclo[4.2.0]octane-3,5-dione [ No CAS ]
  • 24
  • [ 4401-71-2 ]
  • [ 91-20-3 ]
  • 6a,6b,10a,10b-tetrahydro-7,9,10a-trimethylnaphtho[1',2':3,4]cyclobuta[1,2-d]pyrimidine-8,10-dione [ No CAS ]
  • 25
  • [ 25902-89-0 ]
  • [ 77-78-1 ]
  • [ 4160-72-9 ]
  • [ 4401-71-2 ]
  • [ 5151-34-8 ]
  • [ 25902-87-8 ]
  • 26
  • [ 4401-71-2 ]
  • [ 116-15-4 ]
  • (Z)-1,3-dimethyl-6-(perfluoroprop-1-enyl)thymine [ No CAS ]
  • (E)-1,3-dimethyl-6-(perfluoroprop-1-enyl)thymine [ No CAS ]
  • 6-[5-(perfluoroprop-1-enyl)-hexahydro-1,3,5-trimethyl-2,6-dioxopyrimidyn-4-yl]-1,3,5-trimethylpyrimidine-2,4-dione [ No CAS ]
  • 27
  • [ 65-71-4 ]
  • [ 77-78-1 ]
  • [ 4160-77-4 ]
  • [ 4160-72-9 ]
  • [ 4401-71-2 ]
  • 28
  • [ 248609-83-8 ]
  • 1,3-dimethyl-5-(1,3,5-trimethyl-2,4-dioxo-hexahydro-pyrimidin-5-ylmethyl)-1H-pyrimidine-2,4-dione [ No CAS ]
  • [ 4401-71-2 ]
  • 29
  • [ 248609-80-5 ]
  • [ 4401-71-2 ]
  • 30
  • [ 248609-77-0 ]
  • [ 4401-71-2 ]
 

Historical Records

Categories

Related Functional Groups of
[ 4401-71-2 ]

Amides

Chemical Structure| 4869-46-9

A161703 [4869-46-9]

1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde

Similarity: 0.96

Chemical Structure| 65-71-4

A178972 [65-71-4]

5-Methylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.92

Chemical Structure| 546145-03-3

A534934 [546145-03-3]

N-(2-Aminoethyl)-2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide

Similarity: 0.88

Chemical Structure| 4212-49-1

A273638 [4212-49-1]

5-Ethylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.84

Chemical Structure| 20924-05-4

A152627 [20924-05-4]

2-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetic acid

Similarity: 0.83

Related Parent Nucleus of
[ 4401-71-2 ]

Pyrimidines

Chemical Structure| 4869-46-9

A161703 [4869-46-9]

1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde

Similarity: 0.96

Chemical Structure| 65-71-4

A178972 [65-71-4]

5-Methylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.92

Chemical Structure| 546145-03-3

A534934 [546145-03-3]

N-(2-Aminoethyl)-2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide

Similarity: 0.88

Chemical Structure| 4212-49-1

A273638 [4212-49-1]

5-Ethylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.84

Chemical Structure| 20924-05-4

A152627 [20924-05-4]

2-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetic acid

Similarity: 0.83